Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated. The IC50 numbers reported for Axitinib are sub to low nanomolar in range.
Product Details
Alternative Name: | AG-013736 |
|
Formula: | C22H18N4OS |
|
MW: | 386.5 |
|
CAS: | 319460-85-0 |
|
Purity: | ≥95% (HPLC) |
|
Identity: | Determined by EM-MS, NMR |
|
Appearance: | Beige powder. |
|
Solubility: | Soluble in DMSO (42mg/ml) or ethanol (1mg/ml). |
|
Shipping: | Ambient |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | -20°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over